Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NQO1 antisense RNA 1 (NQO1-AS1) is a long non-coding natural antisense transcript transcribed from the opposite strand of the NQO1 gene. It predominantly resides in the cytoplasm and has minimal protein-coding potential. Functionally, NQO1-AS1 regulates its sense partner gene NQO1 post-transcriptionally by binding the 3′ untranslated region (UTR) of NQO1 mRNA, stabilizing it, and increasing the protein expression level. This upregulation protects against oxidative stress and can play a role in disease contexts such as cancer—where elevated NQO1-AS1 promotes breast cancer progression by boosting NQO1, and in COPD—where it dampens cigarette smoke-induced oxidative damage. NQO1-AS1 represents a functionally important noncoding RNA but is not currently considered a direct therapeutic target; its modulation has implications primarily through effects on its sense gene, NQO1.
Not applicable: no drugs are known to directly target NQO1-AS1. For NQO1 modulation by NQO1-AS1: acts through antisense pairing with NQO1 mRNA, increasing its stability and expression post-transcriptionally.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NQO1 antisense RNA 1 (NQO1-AS1).